Semax: What the Evidence Actually Shows

Grade C in the WestPending FDA rulemaking

Status first

Semax is not currently legal to compound in the US. It passed the FDA advisory committee vote 8 to 5 on the second day of the July 2026 hearing, and awaits formal rulemaking.

The short version

A synthetic analog of ACTH (4-10) with the hormonal activity removed.
Developed in Russia and used clinically there for stroke and cognitive indications.
The supporting literature is almost entirely Russian and largely unavailable in English.
Usually administered intranasally rather than injected.
Pending rulemaking. Not available.

What it is

Semax is a heptapeptide derived from adrenocorticotropic hormone, modified so that it retains effects on the central nervous system without the hormonal activity of the parent molecule. It is reported to influence BDNF expression, which is the mechanism most often cited for its cognitive claims.

The evidence problem

Semax has been in clinical use in Russia for decades, and there is a real body of Russian literature behind it. The difficulty is that most of it has not been published in Western journals, has not been independently replicated, and does not meet the methodological standards that would be expected for a Western approval.

That is not the same as saying it does not work. It is saying that the evidence available to you, in a language you can read and from a source you can evaluate, is thin.

What this will not do

It will not come with Western trial data.
It will not treat a diagnosed cognitive condition.
It will not be available until rulemaking completes.

Full library · Safety and sourcing · Reconstitution calculator · Compound index